Atlas Antibodies: Selected partner

Atlas Antibodies, founded by researchers involved in the Human Protein Atlas project, is renowned for producing highly validated research antibodies and advanced reagents for biomedical research.

As part of Atlas Antibodies, evitria now enjoys substantial enhancements in capabilities and resources, enabling it to offer even greater value to its recombinant antibody expression services.

Key facts

  • Specialization: Production of highly validated polyclonal and monoclonal antibodies
  • Technology: Advanced platforms and antibody validation techniques
  • Services: Antibody production services, including recombinant and afucosylated antibodies, as well as a wide range of other research reagents
  • Website: atlasantibodies.com
evitria partnerships with singular focus
evitria partner – Atlas Antibodies

Location

Head Office
Voltavägen 13A (visiting address Voltavägen 13)
SE-168 69 Bromma
Sweden

Sales Office
Ideon Science Park
Scheelevägen 15
SE-223 63 Lund
Sweden

About Atlas Antibodies

Atlas Antibodies was founded in 2006 by researchers from the Royal Institute of Technology and Uppsala University, stemming from the Human Protein Atlas project. The company is dedicated to providing high-quality antibodies and advanced reagents for biomedical research.

Their extensive portfolio includes Triple A Polyclonals, PrecisA Monoclonals, and various other antibody types, which are widely used in cancer, neuroscience, and cell biology research.

Why reliability - evitria partnerships

Our workflow with Atlas Antibodies

01

Box Icon

Catalogue screening


  • Off-the-shelf antibodies for rapid R&D screening & selection
  • Catalogue of >25,000 constructs covering the human proteome
  • Highly characterized and validated mono- and polyclonal preparations

02

Box Icon

Sequencing


03

Box Icon

Recombinant expression


04

Box Icon

Quality control & lot release testing


Unlock the full potential of your research with Atlas Antibodies and evitria

As part of Atlas Antibodies, evitria benefits from enhanced capabilities and resources, enabling it to offer even greater value to its customers. This strategic acquisition combines Atlas Antibodies’ extensive experience in producing highly validated research antibodies with evitria’s expertise in custom recombinant antibody expression.

By integrating evitria’s specialized CHO cell-based transient expression systems with Atlas Antibodies’ validated reagent production, the partnership ensures that researchers receive consistent, high-quality results tailored to their specific needs.

Fc-Silenced Antibodies by evitria

Get in touch with our experts now!

Our team of experts is looking forward to talk with you about your plans, concerns and expectations regarding our expression services.

Lisa Meza San Diego contact at evitria
Richward Park Boston contact at evitria
Dr. Desmond Schofield
Chief Business Officer at evitria
Dr. Stefan Schmidt new CEO of evitria
Please enable JavaScript in your browser to complete this form.
Data protection